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Radiopharmaceutical 99mTc-Glutathione has been developed for 
cancer diagnostic in nuclear medicine. Interactions between chemotherapy 
drugs and radiopharmaceuticals can altered radiopharmaceuticals 
performance.  Drug interaction 5-fluorouracil (5-FU) with a radiop-
harmaceutical 99mTc-Glutathione in mice cancer model has been proven in 
pharmacokinetics study. The biological half-life distribution of 99mTc-
Glutathione for cancer model mice when administrated with 5-FU become 
longer to 0.340±0.121h if compared with 99mTc-Glutathione. Biological half-
life elimination for cancer model mice given with 99mTc-Glutathione is 
72.712±2.427h. Administration of 5-FU makes the biological half-life 
elimination of 99mTc-Glutathione shorter to 17.030±3.459h. Biodistribution 
study of 5-FU continued with 99mTc-Glutathione for cancer model mice 
showed higher physiological uptake in the kidney was observed 
(39.77±2.70%ID/g) for 99mTc-Glutathione has lower uptake on kidney 
(29.55.3.73 %ID/g) with p<0.05. Based on calculation on cancer model mice 
with colon cancer compared with muscle, shown target/non-target (T/NT) 
ratio 2.93 for 5-FU continued with 99mTc-Glutathione has ratio 0.42. Low 
ratio T/NT may affect to poor organ visualization for cancer diagnosis.  
Acute toxicity study has shown drugs safety for clinical purpose. The 
knowledge about chemotherapy drug interaction with a radio-
pharmaceutical is important to have a correct diagnosis of the patient on 
clinical application. 
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Cancer is an important cause of death with 
high morbidity in human. The Global Cancer 
Statistic indicate in 2018, there are 18.1 million new 
cases and 9.6 million deaths from cancer. The 
cumulative risk of incidence of cancer indicates that 
1 in 8 men and 1 in 10 women will develop cancer 
in a lifetime (Bray et al., 2018). Based on Basic 
Health Research in Indonesia 2007, cancer is the 
7th cause of death among all cases with national 
prevalence is 4.3 for 1000 population. The leading 
cancer case are breast cancer, cervical cancer, lung 
cancer and colorectal cancer (Wahidin et al., 2012).  
A radiopharmaceutical is a pharmaceutical 
that   contains   radioactive  isotopes   that  used  for  
diagnostic purposes and treatment of human 
diseases (Saha and Gopal, 2010). Radiopharma-
ceuticals usually don’t have pharmacologic effects, 
unlike conventional drugs. When radiopharma-
ceutical is used for therapeutic purposes there are 
some exceptions. Radiolabeled particles have some 
potential mechanical issues such as the embolic 
effect of 99mTc-macroaggregated albumin and 90Y-
resin particles. A sufficient number of particles 
99mTc-macroaggregated albumin need to be 
administered to avoid a non-uniform spatial 
distribution of radioactivity in lung region. Excess 
of the particles can produce acute toxicity, 
especially in patients with severe pulmonary 
hypertension (Marti, 2013). 
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5-Fluorouracil is an analog of uracil with a 
fluorine atom at the C-5 position in place of the 
hydrogen atom. Mechanism of action 5-
Fluorouracil (5-FU) has rapidly entered the cell 
using the same facilitated transport mechanism as 
uracil then catabolized primarily in the liver. 5-FU 
has been used for more than 40 years in the 
treatment of colorectal cancer. This drugs 
administered intravenously for a clinical procedure 
and has been used in a variety of different schedules 
to determine the optimum dose and method. The 
overall response rate has a good result as a single 
agent for treatment of both advanced and early-
stage colorectal cancer (Longley et al., 2003). 
Researcher was identified 5-FU induce 
senescence cell in both cell types. Signaling 
pathways were activated by senescence cells that 
lead to the production and release of cytokines, 
chemokines, and growth factors to induce 
neighboring cells to enter senescence. 5-FU also 
have a possible mechanism to manifestations of 
cardiotoxicity. In the other hand suggest potential 
prevention strategies to reduce these severe side 
effects of an otherwise very useful drug family for 
the treatment of numerous cancers (Focaccetti et 
al.,  2015). Wongso and Zainuddin (2013), prove 
that 99mTc-Glutathione effectively reaches the 
cancer organ at 3h post-injection with a 
concentration of 0.95% ID/g. The imaging test 
results also showed the highest accumulation of 
99mTc-Glutathione at 3h post-injection and high 
values of renal system. 
Effect of cancer chemotherapeutics drugs 
interaction with radiopharmaceutical has been 
studied for some drugs. Doxorubicin interaction 
with 99mTc-DTPA was observed, mean activity in rat 
urinary system decreased while a significant 
increase in liver uptake. (Razaq et al., 2017). 
Mahendra et al., (2018) were observed interaction 
of NSAID drugs such as meloxicam and sodium 
diclofenac increased clearance of 99mTc-MDP in the 
blood and decrease uptake on the bone of rats.  To 
our knowledge, there has been no report of 
preclinical study interaction 5-FU with 
radiopharmaceutical 99mTc-Glutathione. Thus, we 
aimed to investigate the biodistribution, 
pharmacokinetics and acute toxicity study in 
normal and cancer model mice.  
 
MATERIAL AND METHODS 
Glutathione (Sigma Aldrich), 5-Fluorouracil 
(Kalbe Farma),  SnCl2 (Sigma Aldrich), Na99mTcO4 
was eluted from the commercial 99Mo/99mTc 
generator (Polatom), Acetone, NaCl, TLC-SG 
(Bioscan), aquabidest (IPHA Laboratories), 3MM 
Whatmann chromatography paper and pH 
Universal indicator were obtained from E.Merck. 
The Equipment used too radioactivity counting 




Thirty four male Balb/C mice, 28 days old 
from PT Biofarma, Tbk Bandung, Indonesia were 
housed in polypropylene cages (38X30 cm) at 
constant temperature (26±1ºC) and humidity 
(60±5%) with a 12h dark cycle. The mice were feed 
standard (CP505) and water ad libitum then 
divided into two groups. Group I normal mice; 
group II cancer model mice induce with 
Azoxymethane (Sigma Aldrich) and DSS 2.5% 
(Sigma Aldrich). All protocol was approved by the 
ethics committee for the care and use of laboratory 
animal (KEPPHP BATAN) under protocol number 
002/KEPPHP-BATAN/VII/2018. Mice in Cancer 
model group were induced intraperitoneal by 
Azoxymethane (AOM) dissolved in 0.9% Sodium 
Chloride with doses 10mg/kg BW. After one week 
of induction, mice were given standard feed and ad 
libitum water. Mice were given Dextran Sodium 
Sulfate 2.5% in drinking water for one week and 
then no further treatment for 18 weeks (Tanaka et 
al., 2003). 
 
Preparation of 99mTc-Glutathione 
Preparation of Glutathione dry diagnostic kit 
was performed with 20mg Glutathione dissolved in 
1mL aquabidest while stirring, 0.3mL of SnCl2.2H2O 
(1mg/mL of HCl 0.01N) was added. The pH adjusted 
to pH 7, stirred for a few minutes and filtered. The 
mixture was dried using Freeze Dryer for 22 hours 
and stored at about 4ᵒC. Labeling reaction of the 
99mTc-Glutathione complex was performed with 
added 2.5mL of pertechnetate into glutathione dry 
kit and the mixture was shaken for a few seconds 
and left to react for 5min at room temperature. The 
radiochemical purity of 99mTc-Glutathione complex 
was assessed by TLC using a TLC-SG with two 
solvent, NaCl and dried acetone (Zainuddin and 
Maula, 2010). 
 
Pharmacokinetics study   
Mice were divided into two groups (n=3)  
group I normal mice (99mTc-Glutathione and 5-FU 
continued with 99mTc-Glutathione) and group II 
cancer model mice (99mTc-Glutathione and 5-FU 
continued with 99mTc-Glutathione). Mice were 
treated with 5-FU 0.1mL, after five minutes gave a 
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single intravenous injection in the tail vein with 
99mTc-Glutathione 0.1mL with radioactivity 100µCi. 
Blood collection in time interval 15min, 30min, 1, 2, 
3, 4, 5, 6, 24, 25, and 26h. Blood collected from the 
tail vein and weighing with an analytical scale. The 
radioactivity of the blood sample was measured 
using Single Channel Analyzer with NaI(Tl) 
detector. After radioactivity counting, the 
percentage of total injection dose (%ID) in blood 
were calculated. Pharmacokinetics parameter of 
99mTc-Glutathione was performed using PK Solver 
2.0 (Zhang et al., 2010). 
 
Biodistribution study 
The experiment was performed on Balb/C 
mice weighing approximately 25g. Mice were 
divided into normal group and cancer model        
group (99mTc-Glutathione and 5-FU continued with               
99mTc-Glutathione). The 5-FU was injected into tail 
vein of the animal (0.1mL), after 5min then 99mTc-
Glutathione was given 100µCi into vein tail. Then 
after one hour mice were euthanized and the tissue 
of interest was collected. All tissue and blood were 
weighed and counted for radioactivity using single 
channel analyzer with NaI(Tl) detector. The percent 
of radioctivity per gram of tissue weight (%Injected 
activity/g tissue) was determined using the 
following formula : 
 
%𝐼𝐷 =  
Counts per gram organ
Counts dose given
 X 100% 
 
Toxicity study 
Healthy Balb/C mice were divided into two 
groups, normal and cancer model (n=5). The 5-FU 
was injected into tail vein of the animal (0.1mL), 
after 5min then 99mTc-Glutathione was given 
100µCi into tail vein and animal activity was 
observed shortly after being injected 1, 2, 3, and 
24h, up to 14 days. The following parameters           
were evaluated mortality, clinical observation of 
animal was performed for sickness symptoms  due 
to treatment. Change in their appearance 
(piloerection, kyphosis, disheveled fur), behavior 
(grooming or nesting) and activity (altered 
exploring) (Silveira et al., 2016). 
 
Data analysis 
All average values are given as mean                    
± standard deviation. The comparison of pharmaco-
kinetics parameter and biodistribution of 99mTc-
Glutathione and 5-FU with 99mTc-Glutathione in 
normal mice and cancer model mice was 
determined using t-test. The acceptable probability 
for a significant difference was p<0.05. Data were 
analyzed using SPSS 24 software. 
 
RESULT AND DISCUSSION 
Radiopharmaceutical has a quality 
requirement in the application for in vivo study. 
The quality requirement is clarity, sterility, non-
pyrogenicity, pH and radiochemical purity. In this 
study, radiochemical purity testing was performed 
using two ascending chromatography system. 
Radiochromatogram of 99mTc-Glutathione, where 
aceton used as a mobile phase, 99mTc-Glutathione 
and 99mTcO2 stayed at the origin (Rf=0)                            
while 99mTcO4- moved with the solvent to give              
Rf=1 (Figure 1). Radiochromatogram of 99mTc-
Glutathione where saline solution used as a mobile 
phase 99mTcO2 stayed at the origin (Rf=0) while 
99mTc-Glutathione and 99mTcO4- moved with the 
solvent to give Rf =1 (Figure 2). Result of this                   
test showed that 99mTc-Glutathione had 99.27% 




Figure 1. Radiochromatogram of 99mTc-Glutathione 




Figure 2. Radiochromatogram of 99mTc-Glutathione 
using 0.9% NaCl as mobile phase. 
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This 99mTc-Glutathione radiopharmaceutical 
confirmed to United States of Pharmacopoeia, 
which state that the radiochemical purity has to be 
greater than 95%. The solution was clear and 
colorless with pH = 7. 
 
Pharmacokinetics study 
The pharmacokinetic study was performed 
to determine changes in pharmacokinetics 
parameter of 99mTc-Glutathione in Balb/C mice 
which have been previously treated with 99mTc-
Glutathione and 5-FU continued with 99mTc-
Glutathione. The result (Table I) that the 
administration of 5-FU and followed with 99mTc-
Glutathione affected the pharmacokinetics 
parameter of 99mTc-Glutathione I.V. injection in 
blood both normal mice and cancer model.  
The result of t-test for pharmacokinetics 
parameter (Table I), in normal mice there was 
significant difference p<0.05 for biological half-life 
elimination of 99mTc-Glutathione when 
administrated with 5-FU become longer to 
11.497±2.827 h. Biological half-life distribution and 
elimination of 99mTc-Glutathione for cancer model 
mice when administrated with 5-FU also changed, 
biological half-life distribution become longer to 
0.340±0.121 hours and biological half-life 
elimination become shorter to 17.030±3.459 hours 
compared with 99mTc-Glutathione single 
administration 72.712±2.427h. 
Administration of 5-FU followed with 99mTc-
Glutathione I.V. injection also change AUC0-inf value 
(area under the curve) and C-max (peak 
concentration) from normal and cancer model mice 
compared with 99mTc-Glutathione  but not 
significantly different (p>0.05) based on statistical 
analysis. 99mTc-Glutathione and combined with 5-
FU has the same absorption rate for normal and 
cancer model mice. 
Radioactivity half-life of radiopharma-
ceutical in blood can be approximated by two 
phases. The first is distribution half-life that is 
during radioactive material spreads throughout 
various organs or tissues, reaching organ specific 
concentrations. The second is elimination half-life, 
the material is eliminated by biochemical processes 
and physical radioisotope decay (Shuryak and 
Dadachova, 2015).  
The localization mechanism of 99mTc-
Glutathione has never been clarified but in general 
99mTc-Glutathione increased in blood flow and 
capillary permeability are the main mechanism. 
The blood clearance and wash out of 99mTc-
Glutathione from tumoral and another tissue was 
not rapid because protein binding at the site of 
localization might occur for the prolonged retention 
of 99mTc-Glutathione on target tissue (Ercan and 
Senekowitsch-schmidtke, 2000), it has been  
proven in cancer model mice showed the biological 
half-life elimination (t1/2β) become prolonged. 
Administration of 5-FU continued with 99mTc-
Glutathione in cancer model mice also made the 
blood clearance faster may occur because of 5-FU 
binding the site of localization in the organ but the 
mechanism it has not been clear. 
Compared with normal mice group, 5-FU 
administration followed with 99mTc-Glutathione 
causing the half-life elimination (t1/2β) to be 
longer, this is probably due to 5-FU causes retention 
of 99mTc-Glutathione and radioactivity become 
prolonged on the blood. 
 
Biodistribution study 
Biodistribution of 99mTc-Glutathione and                
5-FU in normal and cancer model mice were 
studied at 1h post-injection to evaluate the 
accumulation  of radiopharmaceutical. Based on 
data for normal mice higher physiological uptake of 
Table I. Pharmacokinetics parameter of 99mTc-Glutathione and interaction of 5-FU with 99mTc-Glutathione 














K12 0.001±0.001 0.001±0.001 NS 0.003±0.003 0.017±0.027 NS 
K21 0.134±0.275 0.033±0.027 S 0.067±0.099 0.019±0.017 NS 
Cmaks 6.132±5.161 3.299±0.879 NS 2.436±0.569 3.766±2.677 NS 
t1/2 α 0.004±0.001 0.347±0.225 NS 0.003±0.000 0.340±0.121 S 
t1/2 β 5.310±1.050 11.497±2.827 S 72.712±2.427 17.030±3.459 S 
AUC 0-inf 12.264±10.322 6.931±1.181 NS 4.343±1.159 7.533±5.355 NS 
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99mTc-Glutathione in the kidney was observed in 
this work (36.88±6.89%ID/g) it was so administer 
level 5-FU continued with 99mTc-Glutathione 
(44.20±7.74%ID/g). The second organ with the 
highest accumulation was the bone, 
(7.71±1.58%ID/g) and (10.10±4.28%ID/g) 
respectively. Lower uptake in other organ 1 hour 
after injection: was muscle (1.13±0.76%ID/g) 
(0.94±0.40%ID/g), hearth (1.87±1.03%ID/g) 
(1.70±0.84%ID/g), and stomach (1.77±0.45 %ID/g) 
(3.73±2.75%ID/g). Administration of 99mTc-
Glutathione compared with 5-FU followed with 
99mTc-Glutathione change the biodistribution value 
for organ in normal mice but not significantly 




Figure 3. Biodistribution of 99mTc-Glutathione and 





Figure 4. Biodistribution of 99mTc-Glutathione and 
5-Flurouracil with 99mTc-Glutathione in cancer 
model mice (1h) 
 
Administration of 5-FU followed with                
99mTc-Glutathione for cancer model mice (Figure 4) 
showed higher physiological uptake in the               
kidney. The uptake in kidney was observed 
(39.77±2.70%ID/g). However when 99mTc-
Glutathione was administered with 5-FU, the 
uptake of glutathione was lower (29.55.3.73 
%ID/g). The present work shows that some 
accumulation of 99mTc-Glutathione on the organ. 
Intestinal accumulation on normal mice due to 
biliary excretion of the agent and in cancer model 
mice the agent delivered to cancer tissue. Blood and 
extravascular fluid compartment also contribute to 
distribution to all organ. 
The result of t-test between normal and 
cancer model group for organ showed there was no 
significant difference in biodistribution between 
administration of 99mTc-Glutathione and 5-FU 
followed with 99mTc-Glutathione p>0.05 for normal 
mice. Biodistribution of 99mTc-Glutathione  on 
cancer model mice showed data was significantly 
different increased the 99mTc-Glutathione level to 
the kidney. High concentration on kidney due to the 
metabolism of 99mTc agents on renal system. 
Administration of 5-FU increased the retention of 
99mTc-Glutathione on kidney and reach high 
concentration. 5-FU interaction with 99mTc-
Glutathione based on biodistribution study 
compared data in both normal and cancer mice do 
not affect the physiologic state of the target organs.  
99mTc-Glutathione is higly water soluble 
complex with a negative charge and could be 
secreted through the renal tubule if it posses 
anionic properties. Interaction of drug with 
radiopharmaceutical may arise as a result of a 
variety of factors including the pharmacological 
action of the drug, physiochemical interactions 
between drugs and radiotracers, and competition 
for binding sites for example. Diseases induced by 
drugs, which may be potentiated by a radio-
pharmaceutical, would also be considered an 
adverse event (Oliveira et al., 2008). 
5-FU is anticancer drug that has been            
used to treat various type of malignancies cancer. 
This drug was catabolized to inactive metabolites 
by dihydropyrimidine dehydrogenase (DPD), 
cytotoxic effects on tumor cells and normal tissues 
through anabolic actions. 5-FU was inhibiting                  
DNA synthesis which in turn affect RNA 
transcription and function. The 5-FU metabolite, 
fluorodeoxyuridine mono-phosphate (FdUMP), 
forms a ternary complex with thymidylate  
synthase (TS) and 5,10-methylene tetrahydrofolate 
(CH2THF), thereby inhibiting the synthesis of DNA 
(Miura et al., 2010). 
Several studies have investigated used 99mTc-
Glutathione as a tumor-specific imaging agent. 
Cancer cell if compared with normal cell posses 
higher Reactive  Oxygen Species (ROS) level and 
enhanced antioxidant system (Woo et al., 2014). 
Ercan & Senekowitsch-schmidtke (2000) was 
observed that 99mTc-Glutathione has a significant 
increase in tumor uptake at 1h post-injection with 
tumor 3.27±0.80% injected dose/g. Uptake may 
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decrease at 3h post-injection, because of 
Glutathione mechanism of action.  
Availability of 99mTc-Glutathione to be used 
in cancer patient under treatment of 5-FU is not 
recommended if we compare between the target 
and non-target.  Based on calculation on cancer 
model mice with colon cancer compared with 
muscle shown target/non-target (T/NT) ratio 2.93 
whereas, if 5-FU followed by 99mTc-Glutathione has 
ratio 0.42. Low ratio T/NT may affect to poor organ 
visualization for cancer diagnosis.  
 
Toxicity study result 
No death or clinical sign of peracute toxicity 
was observed in normal and cancer model groups 
during the 14-days study period. All the animals 
seemed healthy throughout the course of the study. 
No signs of distress, morbidity, injury or changes in 
behavior shortly after being injected with 5-FU and 
99mTc-Glutathione, 1, 2, 3, 24 hours, and 14 days. 
 
CONCLUSION 
The knowledge about chemotherapy drug 
interaction with a radiopharmaceutical is 
important to determine the correct diagnosis of the 
patient in clinical application. The present work 
was designed to study 5-FU interaction with 99mTc-
Glutathione both in normal and cancer model mice. 
Change in pharmacokinetics parameters occur in 5-
FU administration followed by 99mTc-Glutathione 
especially in the biological half-life of cancer mice, 
the biological half-life elimination becomes longer 
and biological half-life biodistribution become 
faster. Biodistribution studies show that 5-FU 
administration followed by 99mTc-Glutathione does 
not change the uptake of 99mTc-Glutathione in 
normal mice but in cancer model mice the uptake in 
kidney significantly increased. Further study is 
needed to understand the cellular mechanism for 5-
FU interaction with 99mTc-Glutathione. 
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